Anti-PD1/PD-L1 antibodies have become the standard frontline treatment, as a single agent when PD-L1 tumor expression is high or combined with chemotherapy otherwise [1,2,3,4,5,6,7,8]. This evidence concerns the gene CD274 and neoplasm.